Aquestive Advances Anaphylm Resubmission Amid Strong Manufacturing Growth
Event summary
- Aquestive completed key studies for Anaphylm resubmission, targeting Q3 2026 FDA filing
- Manufacturing revenue grew 24% YoY to $11.9M in Q2 2026
- Company maintains $46–50M revenue guidance despite $22.9M net loss
- AQST-108 dermatology program expands into atopic dermatitis
The big picture
Aquestive's strategic focus on non-invasive epinephrine delivery positions it to challenge autoinjector dominance, while its manufacturing business provides stable revenue amid clinical development. The company's ability to convert regulatory setbacks into refined commercial strategies will determine its market penetration potential.
What we're watching
- Regulatory Timing
- Whether FDA will grant expedited review for Anaphylm resubmission
- Commercial Readiness
- Pace of allergist engagement ahead of potential 2027 launch
- Pipeline Expansion
- Progress in AQST-108 dermatology indications beyond alopecia
Related topics